Korea Investment CORP Raises Stock Position in Incyte Corporation $INCY

Korea Investment CORP increased its position in shares of Incyte Corporation (NASDAQ:INCY) by 190.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 229,326 shares of the biopharmaceutical company’s stock after acquiring an additional 150,300 shares during the quarter. Korea Investment CORP owned about 0.12% of Incyte worth $19,449,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Harbor Capital Advisors Inc. purchased a new position in Incyte in the third quarter worth $26,000. Root Financial Partners LLC acquired a new position in shares of Incyte during the third quarter worth $28,000. Quent Capital LLC purchased a new stake in shares of Incyte during the 3rd quarter valued at $30,000. MUFG Securities EMEA plc purchased a new stake in shares of Incyte during the 2nd quarter valued at $32,000. Finally, CYBER HORNET ETFs LLC acquired a new stake in shares of Incyte in the 2nd quarter worth $33,000. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Incyte news, insider Thomas Tray sold 2,774 shares of Incyte stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $100.00, for a total transaction of $277,400.00. Following the completion of the transaction, the insider owned 22,973 shares in the company, valued at approximately $2,297,300. This trade represents a 10.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Mohamed Khairie Issa sold 10,856 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total value of $1,184,063.92. Following the completion of the transaction, the executive vice president directly owned 66,132 shares of the company’s stock, valued at approximately $7,213,017.24. This trade represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 72,561 shares of company stock valued at $7,195,307 over the last 90 days. Insiders own 17.80% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on INCY shares. Weiss Ratings raised Incyte from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, March 2nd. Wells Fargo & Company decreased their price target on Incyte from $107.00 to $101.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 11th. Royal Bank Of Canada dropped their price target on Incyte from $95.00 to $92.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 11th. The Goldman Sachs Group restated a “neutral” rating and set a $90.00 price objective on shares of Incyte in a report on Thursday, January 8th. Finally, Stifel Nicolaus increased their price objective on shares of Incyte from $119.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Ten equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $104.00.

Incyte Trading Down 1.1%

Incyte stock opened at $96.02 on Wednesday. The stock has a 50-day moving average price of $102.18 and a 200 day moving average price of $96.47. The company has a market capitalization of $19.11 billion, a price-to-earnings ratio of 14.98, a price-to-earnings-growth ratio of 0.77 and a beta of 0.84. Incyte Corporation has a 52 week low of $53.56 and a 52 week high of $112.29. The company has a quick ratio of 3.25, a current ratio of 3.32 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing the consensus estimate of $1.96 by ($0.16). Incyte had a return on equity of 26.34% and a net margin of 25.03%.The business had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.35 billion. During the same quarter last year, the company posted $1.43 EPS. Incyte’s quarterly revenue was up 27.8% compared to the same quarter last year. Sell-side analysts anticipate that Incyte Corporation will post 4.86 EPS for the current year.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.